

**Daclatasvir**

## Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations  
 Oral > Solid > tablet: 30 mg (as hydrochloride); 60 mg (as hydrochloride)

## Indications

Chronic hepatitis C

**Daclatasvir + sofosbuvir**

## Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations  
 Oral > Solid > tablet: 60 mg + 400 mg

## Indications

Chronic hepatitis C

**Dasabuvir**

## Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations  
 Oral > Solid: 250 mg tablet

## Indications

Chronic hepatitis C

**Elbasvir + grazoprevir**

## Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations  
 Oral > Solid: 50 mg + 100 mg

## Indications

Chronic hepatitis C

**Entecavir**

## Section

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors  
 Oral > Liquid: 0.05 mg per mL  
 Oral > Solid: 0.5 mg; 1 mg

## Indications

Chronic hepatitis B

**Glecaprevir + pibrentasvir**

## Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations  
 Oral > Solid: 50 mg + 20 mg granules  
 Oral > Solid > tablet: 100 mg + 40 mg

## Indications

Chronic hepatitis C

## Ledipasvir + sofosbuvir

### Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations  
Oral > Solid: 90 mg + 400 mg tablet

### Indications

Chronic hepatitis C

## Ombitasvir + paritaprevir + ritonavir

### Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations  
Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet

### Indications

Chronic hepatitis C

## Pegylated interferon alfa (2a)

### Section

Medicines for hepatitis C > Other antivirals for hepatitis C  
Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe

### Indications

Chronic hepatitis C

## Pegylated interferon alfa (2b)

### Section

Medicines for hepatitis C > Other antivirals for hepatitis C  
Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe

### Indications

Chronic hepatitis C

## Ravidasvir

### Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations  
Oral > Solid > tablet: 200 mg

### Indications

Chronic hepatitis C

## Ribavirin

### Section

Medicines for hepatitis C > Other antivirals for hepatitis C  
Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution  
Oral > Solid: 200 mg; 400 mg; 600 mg

### Indications

Chronic hepatitis C

## Simeprevir

### Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations  
Oral > Solid: 150 mg

### Indications

Chronic hepatitis C

## Sofosbuvir

### Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations  
Oral > Solid > tablet: 200 mg; 400 mg

### Indications

Chronic hepatitis C

## Sofosbuvir + velpatasvir

### Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations  
Oral > Solid > tablet: 200 mg + 50 mg; 400 mg + 100 mg

### Indications

Chronic hepatitis C

## Tenofovir alafenamide

### Section

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors  
Oral > Solid: 25 mg

### Indications

Chronic hepatitis B

## Tenofovir disoproxil fumarate

### Section

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors  
Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)

### Indications

Chronic hepatitis B